AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Recursion Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) director Franziska Michor received new equity compensation on June 18, 2025, consisting of two components:

  • 22,016 restricted stock units (RSUs) granted under the Outside Director Compensation Policy, which will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
  • 44,031 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs

Following these transactions, Michor directly owns 127,053 shares of Class A Common Stock and 44,031 stock options. Both grants are subject to continued service as a director. This filing represents standard board of director equity compensation and indicates the company's commitment to aligning director interests with shareholders through equity-based compensation.

Franziska Michor, direttrice di Recursion Pharmaceuticals (RXRX), ha ricevuto una nuova remunerazione in azioni il 18 giugno 2025, composta da due elementi:

  • 22.016 unità azionarie vincolate (RSU) concesse secondo la Politica di Compensazione per Direttori Esterni, che matureranno il 18 giugno 2026 o il giorno prima dell'Assemblea Annuale 2026, se precedente
  • 44.031 opzioni su azioni con un prezzo di esercizio di 5,11 dollari, esercitabili fino al 18 giugno 2035, con un piano di maturazione identico a quello delle RSU

Dopo queste operazioni, Michor detiene direttamente 127.053 azioni di Classe A e 44.031 opzioni su azioni. Entrambi i premi sono subordinati al mantenimento del ruolo di direttore. Questa comunicazione rappresenta una normale compensazione azionaria per il consiglio di amministrazione e sottolinea l'impegno dell'azienda a far convergere gli interessi dei direttori con quelli degli azionisti tramite la remunerazione basata su azioni.

Franziska Michor, directora de Recursion Pharmaceuticals (RXRX), recibió una nueva compensación en acciones el 18 de junio de 2025, que consta de dos componentes:

  • 22,016 unidades restringidas de acciones (RSU) otorgadas bajo la Política de Compensación para Directores Externos, que se consolidarán el 18 de junio de 2026 o el día antes de la Reunión Anual de 2026, lo que ocurra primero
  • 44,031 opciones sobre acciones con un precio de ejercicio de $5.11, ejercitables hasta el 18 de junio de 2035, con un calendario de consolidación igual al de las RSU

Tras estas transacciones, Michor posee directamente 127,053 acciones Clase A y 44,031 opciones sobre acciones. Ambas concesiones están sujetas a la continuidad en el cargo de directora. Esta presentación representa una compensación estándar en acciones para la junta directiva e indica el compromiso de la empresa de alinear los intereses de los directores con los de los accionistas mediante compensación basada en acciones.

Recursion Pharmaceuticals (RXRX)ì� ì´ì‚¬ Franziska MichorëŠ� 2025ë…� 6ì›� 18ì� ë‘� 가지 구성 요소ë¡� ì´ë£¨ì–´ì§„ 새로ìš� ì£¼ì‹ ë³´ìƒì� 받았습니ë‹�:

  • 22,016ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ëŠ� 외부 ì´ì‚¬ ë³´ìƒ ì •ì±…ì—� ë”°ë¼ ë¶€ì—¬ë˜ì—ˆìœ¼ë©�, 2026ë…� 6ì›� 18ì� ë˜ëŠ” 2026ë…� 정기 주주ì´íšŒ ì „ë‚  ì¤� 빠른 ë‚ ì§œì—� 권리가 확정ë©ë‹ˆë‹�
  • 44,031ê°œì˜ ì£¼ì‹ ë§¤ìˆ˜ ì˜µì…˜ì€ í–‰ì‚¬ê°€ê²©ì´ $5.11ì´ë©°, 2035ë…� 6ì›� 18ì¼ê¹Œì§€ 행사 가능하ê³� RSU와 ë™ì¼í•� ì¼ì •으로 권리가 확정ë©ë‹ˆë‹�

ì� 거래 ì´í›„ MichorëŠ� í´ëž˜ìŠ� A 보통ì£� 127,053주와 44,031ê°œì˜ ì£¼ì‹ ë§¤ìˆ˜ 옵션ì� ì§ì ‘ 보유하게 ë©ë‹ˆë‹�. ë‘� ë³´ìƒ ëª¨ë‘ ì´ì‚¬ë¡œì„œì� ì§€ì†ì ì� 근무ë¥� 조건으로 합니ë‹�. ì´ë²ˆ ë³´ê³ ëŠ� ì´ì‚¬íš� ì£¼ì‹ ë³´ìƒì� 표준 사례ì´ë©°, 회사가 ì£¼ì‹ ê¸°ë°˜ ë³´ìƒì� 통해 ì´ì‚¬ì™€ 주주ì� ì´ìµì� ì¼ì¹˜ì‹œí‚¤ë ¤ëŠ” ì˜ì§€ë¥� 나타냅니ë‹�.

Franziska Michor, administratrice de Recursion Pharmaceuticals (RXRX), a reçu une nouvelle rémunération en actions le 18 juin 2025, composée de deux éléments :

  • 22 016 unités d’actions restreintes (RSU) accordées selon la politique de rémunération des administrateurs externes, qui seront acquises au plus tôt le 18 juin 2026 ou la veille de l’assemblée générale 2026
  • 44 031 options d’achat d’actions avec un prix d’exercice de 5,11 $, exerçables jusqu’au 18 juin 2035, avec un calendrier d’acquisition identique à celui des RSU

À la suite de ces opérations, Michor détient directement 127 053 actions ordinaires de catégorie A et 44 031 options d’achat d’actions. Ces deux attributions sont conditionnées à la poursuite de son mandat d’administratrice. Ce dépôt représente une rémunération en actions standard pour le conseil d’administration et illustre l’engagement de la société à aligner les intérêts des administrateurs sur ceux des actionnaires par une rémunération basée sur des actions.

Franziska Michor, Direktorin von Recursion Pharmaceuticals (RXRX), erhielt am 18. Juni 2025 eine neue Aktienvergütung, die aus zwei Komponenten besteht:

  • 22.016 Restricted Stock Units (RSUs), gewährt gemäß der Vergütungspolitik für externe Direktoren, die entweder am 18. Juni 2026 oder am Tag vor der Hauptversammlung 2026 vesten, je nachdem, was zuerst eintritt
  • 44.031 Aktienoptionen mit einem Ausübungspreis von 5,11 USD, ausübbar bis zum 18. Juni 2035, mit demselben Vesting-Zeitplan wie die RSUs

Nach diesen Transaktionen besitzt Michor direkt 127.053 Aktien der Klasse A sowie 44.031 Aktienoptionen. Beide Zuteilungen unterliegen der Bedingung der fortgesetzten Tätigkeit als Direktorin. Diese Meldung stellt eine übliche Aktienvergütung für den Vorstand dar und zeigt das Engagement des Unternehmens, die Interessen der Direktoren durch aktienbasierte Vergütung mit denen der Aktionäre in Einklang zu bringen.

Positive
  • None.
Negative
  • None.

Franziska Michor, direttrice di Recursion Pharmaceuticals (RXRX), ha ricevuto una nuova remunerazione in azioni il 18 giugno 2025, composta da due elementi:

  • 22.016 unità azionarie vincolate (RSU) concesse secondo la Politica di Compensazione per Direttori Esterni, che matureranno il 18 giugno 2026 o il giorno prima dell'Assemblea Annuale 2026, se precedente
  • 44.031 opzioni su azioni con un prezzo di esercizio di 5,11 dollari, esercitabili fino al 18 giugno 2035, con un piano di maturazione identico a quello delle RSU

Dopo queste operazioni, Michor detiene direttamente 127.053 azioni di Classe A e 44.031 opzioni su azioni. Entrambi i premi sono subordinati al mantenimento del ruolo di direttore. Questa comunicazione rappresenta una normale compensazione azionaria per il consiglio di amministrazione e sottolinea l'impegno dell'azienda a far convergere gli interessi dei direttori con quelli degli azionisti tramite la remunerazione basata su azioni.

Franziska Michor, directora de Recursion Pharmaceuticals (RXRX), recibió una nueva compensación en acciones el 18 de junio de 2025, que consta de dos componentes:

  • 22,016 unidades restringidas de acciones (RSU) otorgadas bajo la Política de Compensación para Directores Externos, que se consolidarán el 18 de junio de 2026 o el día antes de la Reunión Anual de 2026, lo que ocurra primero
  • 44,031 opciones sobre acciones con un precio de ejercicio de $5.11, ejercitables hasta el 18 de junio de 2035, con un calendario de consolidación igual al de las RSU

Tras estas transacciones, Michor posee directamente 127,053 acciones Clase A y 44,031 opciones sobre acciones. Ambas concesiones están sujetas a la continuidad en el cargo de directora. Esta presentación representa una compensación estándar en acciones para la junta directiva e indica el compromiso de la empresa de alinear los intereses de los directores con los de los accionistas mediante compensación basada en acciones.

Recursion Pharmaceuticals (RXRX)ì� ì´ì‚¬ Franziska MichorëŠ� 2025ë…� 6ì›� 18ì� ë‘� 가지 구성 요소ë¡� ì´ë£¨ì–´ì§„ 새로ìš� ì£¼ì‹ ë³´ìƒì� 받았습니ë‹�:

  • 22,016ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ëŠ� 외부 ì´ì‚¬ ë³´ìƒ ì •ì±…ì—� ë”°ë¼ ë¶€ì—¬ë˜ì—ˆìœ¼ë©�, 2026ë…� 6ì›� 18ì� ë˜ëŠ” 2026ë…� 정기 주주ì´íšŒ ì „ë‚  ì¤� 빠른 ë‚ ì§œì—� 권리가 확정ë©ë‹ˆë‹�
  • 44,031ê°œì˜ ì£¼ì‹ ë§¤ìˆ˜ ì˜µì…˜ì€ í–‰ì‚¬ê°€ê²©ì´ $5.11ì´ë©°, 2035ë…� 6ì›� 18ì¼ê¹Œì§€ 행사 가능하ê³� RSU와 ë™ì¼í•� ì¼ì •으로 권리가 확정ë©ë‹ˆë‹�

ì� 거래 ì´í›„ MichorëŠ� í´ëž˜ìŠ� A 보통ì£� 127,053주와 44,031ê°œì˜ ì£¼ì‹ ë§¤ìˆ˜ 옵션ì� ì§ì ‘ 보유하게 ë©ë‹ˆë‹�. ë‘� ë³´ìƒ ëª¨ë‘ ì´ì‚¬ë¡œì„œì� ì§€ì†ì ì� 근무ë¥� 조건으로 합니ë‹�. ì´ë²ˆ ë³´ê³ ëŠ� ì´ì‚¬íš� ì£¼ì‹ ë³´ìƒì� 표준 사례ì´ë©°, 회사가 ì£¼ì‹ ê¸°ë°˜ ë³´ìƒì� 통해 ì´ì‚¬ì™€ 주주ì� ì´ìµì� ì¼ì¹˜ì‹œí‚¤ë ¤ëŠ” ì˜ì§€ë¥� 나타냅니ë‹�.

Franziska Michor, administratrice de Recursion Pharmaceuticals (RXRX), a reçu une nouvelle rémunération en actions le 18 juin 2025, composée de deux éléments :

  • 22 016 unités d’actions restreintes (RSU) accordées selon la politique de rémunération des administrateurs externes, qui seront acquises au plus tôt le 18 juin 2026 ou la veille de l’assemblée générale 2026
  • 44 031 options d’achat d’actions avec un prix d’exercice de 5,11 $, exerçables jusqu’au 18 juin 2035, avec un calendrier d’acquisition identique à celui des RSU

À la suite de ces opérations, Michor détient directement 127 053 actions ordinaires de catégorie A et 44 031 options d’achat d’actions. Ces deux attributions sont conditionnées à la poursuite de son mandat d’administratrice. Ce dépôt représente une rémunération en actions standard pour le conseil d’administration et illustre l’engagement de la société à aligner les intérêts des administrateurs sur ceux des actionnaires par une rémunération basée sur des actions.

Franziska Michor, Direktorin von Recursion Pharmaceuticals (RXRX), erhielt am 18. Juni 2025 eine neue Aktienvergütung, die aus zwei Komponenten besteht:

  • 22.016 Restricted Stock Units (RSUs), gewährt gemäß der Vergütungspolitik für externe Direktoren, die entweder am 18. Juni 2026 oder am Tag vor der Hauptversammlung 2026 vesten, je nachdem, was zuerst eintritt
  • 44.031 Aktienoptionen mit einem Ausübungspreis von 5,11 USD, ausübbar bis zum 18. Juni 2035, mit demselben Vesting-Zeitplan wie die RSUs

Nach diesen Transaktionen besitzt Michor direkt 127.053 Aktien der Klasse A sowie 44.031 Aktienoptionen. Beide Zuteilungen unterliegen der Bedingung der fortgesetzten Tätigkeit als Direktorin. Diese Meldung stellt eine übliche Aktienvergütung für den Vorstand dar und zeigt das Engagement des Unternehmens, die Interessen der Direktoren durch aktienbasierte Vergütung mit denen der Aktionäre in Einklang zu bringen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Michor Franziska

(Last) (First) (Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET

(Street)
SALT LAKE CITY UT 84101

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/18/2025 A(1) 22,016 A $0 127,053 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $5.11 06/18/2025 A 44,031 (2) 06/18/2035 Class A Common Stock 44,031 $0 44,031 D
Explanation of Responses:
1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
Remarks:
/s/ Jonathan Golightly, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock grants did RXRX director Franziska Michor receive on June 18, 2025?

Director Franziska Michor received two equity grants on June 18, 2025: (1) 22,016 restricted stock units (RSUs) that vest on June 18, 2026 or before the 2026 Annual Meeting, and (2) stock options to purchase 44,031 shares at $5.11 per share, which vest on the same schedule.

When do Franziska Michor's RXRX stock options expire?

The stock options granted to Franziska Michor on June 18, 2025 expire on June 18, 2035, giving her a 10-year period to exercise the options once vested.

How many shares of RXRX does Franziska Michor own after the June 2025 grants?

Following the reported transactions, Franziska Michor directly owns 127,053 shares of RXRX Class A Common Stock, plus 44,031 stock options. All holdings are listed as Direct (D) ownership.

What is the vesting schedule for RXRX director Michor's June 2025 RSU grant?

The RSU grant will vest on the earlier of two dates: June 18, 2026, or the day before RXRX's 2026 Annual Meeting of Stockholders, subject to Michor's continued service as a director.

What was the exercise price of RXRX stock options granted to Director Michor?

The stock options were granted with an exercise price of $5.11 per share, allowing Director Michor to purchase RXRX Class A Common Stock at this price once the options vest.
Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

RXRX Rankings

RXRX Latest News

RXRX Latest SEC Filings

RXRX Stock Data

2.46B
406.37M
4.78%
69.05%
26.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SALT LAKE CITY